ERCC1 expression is a predictor of survival in gastric cancer patients treated with surgery and adjuvant chemotherapy

Chinese-German Journal of Clinical Oncology

Volumn 10, Issue 2, 2011, Pages 92-95

  Li, Qiang ^a   Dang, Chengxue ^a   Liu, Zhigang ^a   Sun, Ruifang ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; ERCC1; Gastric cancer; Oxaliplatin; Survival

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; OXALIPLATIN;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; SEX DIFFERENCE; STOMACH CANCER; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 79956037262     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-011-0739-1     Document Type: Article

References (14)

1. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol, 2006, 20: 633-649. (Pubitemid 44391336)
2. Li GC, Zhang YL, Zhang M. An analysis of global cancer incidence and mortality trendency from 1999 to 2002. Bull Chin Cancer (Chinese), 2008, 8: 646-649.
3. Yang L, Li LD, Chen YD, et al. Cancer incidence and mortality estimates and prediction for year 2000 and 2005 in China. Chin J Health Stat (Chinese), 2005, 4: 218-221.
4. Paoletti X, Oba K, Burzykowski T, et al. Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis. JAMA, 2010, 303: 1729-1737.
5. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355: 11-20.
6. Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg, 2009, 96: 26-33.
7. Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: acomparison of doxorubicin and sunitinib. Drug Resist Updat, 2009, 12: 114-126.
8. Wei J, Zou Z, Qian X, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer, 2008, 98: 1398-1402. (Pubitemid 351543582)
9. Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 2009; 64: 98-104.
10. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res, 2005, 11: 2215-2221.
11. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 2006, 355: 983-991. (Pubitemid 44343542)
12. Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol, 2007, 18: 504-509. (Pubitemid 46359630)
13. Bramson J, Panasci LC. Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents. Cancer Res, 1993, 53: 3237-3240. (Pubitemid 23223288)
14. Matsubara J, Nishina T, Yamada Y, et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer, 2008, 98: 832-839. (Pubitemid 351272605)